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The malaria vaccine Combination B comprises recombinant Plasmodium falciparum ring–
infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) for-
mulated in oil-based adjuvant. A phase 1– 2b double-blind, randomized, placebo-controlled
trial in 120 children (5–9 years old) in Papua New Guinea demonstrated a 62% (95% confidence
limits: 13%, 84%) reduction in parasite density in children not pretreated with sulfadoxine-
pyrimethamine. Vaccinees had a lower prevalence of parasites carrying the MSP2-3D7 allelic
form (corresponding to that in the vaccine) and a higher incidence of morbid episodes associated
with FC27-type parasites. These results demonstrate functional activity of Combination B
against P. falciparum in individuals with previous malaria exposure. The specific effects on para-
sites with particular msp2 genotypes suggest that the MSP2 component, at least in part, ac-
counted for the activity. The vaccine-induced selection pressure exerted on the parasites and
its consequences for morbidity strongly argue for developing vaccines comprising conserved
antigens and/or multiple components covering all important allelic types.
An effective malaria vaccine will represent a cost-effective
and sustainable addition to the currently available malaria con-
trol interventions [1]. Anti–asexual blood-stage vaccines are
aimed at reducing parasite growth and multiplication in the blood
and, hence, the occurrence or severity of symptoms [2]. Such
vaccines should reduce morbidity and mortality due to malaria
in the most susceptible groups (i.e., children ,5 years old and
pregnant women) living in areas where malaria is endemic.
Here, we report a trial of a vaccine against asexual blood
stages of Plasmodium falciparum. The vaccine comprises mer-
ozoite surface protein (MSP) 1, the 3D7 allele of MSP2, and the
ring-infected erythrocyte surface antigen (RESA). Laboratory
and animal studies indicate that immune responses against these
antigens induce protective immune responses (reviewed in [3]).
Longitudinal seroepidemiologic studies conducted by the Papua
New Guinea Institute of Medical Research [4] also found a
negative correlation between baseline levels of naturally ac-
quired immune responses to these antigens and subsequent
malaria morbidity [5–7].
A series of safety and immunogenicity trials performed in
malaria-naive Australians, first with the adjuvant (Montanide
ISA720) alone [8] and then using different administration and
dose regimens of the vaccine formulation (Combination B) [9],
showed that the product was safe and immunogenic. There was
no precedent for a trial of a malaria vaccine comprising only
blood-stage antigens in a previously exposed population, and
no decisive test of efficacy, short of a field trial, was possible.
Immune responses to the vaccine were considered to be likely
to modify the course of infection without necessarily preventing
it; therefore, the validated artificial challenge protocols used for
pre-erythrocytic vaccines were not appropriate. The phase 2a
trial showed that the vaccine did not modify the course of infec-
tion in malaria-naive individuals [3], but we considered this to
be more likely to happen in semi-immune children, in whom
immunization may boost immune responses primed by natural
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exposure. Furthermore, in the field trial, there was an oppor-
tunity for immune responses to the vaccine to be boosted by
subsequent infection. This was not possible in the phase 2a
trial because of early drug treatment following the laboratory
challenge.
A phase 1 trial in immune adult volunteers living in an area of
Papua New Guinea where malaria is highly endemic indicated
that Combination B was also safe in this population and did not
predispose to serious malaria after subsequent infection [10].
These results led us to proceed with a phase 1–2b trial in the
same area to assess pilot efficacy in children 5–9 years of age.
We did not want to embark on a large-scale trial without any
indication that the vaccine might work; therefore, we designed
a trial with parasite density, which was assessed every 2 weeks
over a 10-week period (weeks 8–18), as a surrogate marker of
protection. Parasitologic outcomes are appropriate measures for
testing asexual blood-stage vaccines that are intended to reduce
parasite multiplication. Parasite density was expected to be a
statistically more powerful outcome measure than the incidence
of morbid episodes, making it possible to study efficacy with
only a small sample size. For safety purposes, clinical episodes
were monitored over an extended period (up to week 76), and
this allowed a preliminary assessment of the vaccine’s impact
on morbidity as a secondary outcome.
A polymerase chain reaction (PCR) technique was used to
determine prevalence, incidence of new infections, and parasite
genotypes. All blood samples collected during the trial were geno-
typed using the highly polymorphic msp2 locus as a marker.
MSP2 alleles fall into 2 families (FC27 and 3D7) defined by a
central dimorphic region flanked by conserved regions [11].
Only the 3D7 form of MSP2 was included in Combination B;
thus, if the vaccine was efficacious, specific effects were ex-
pected on parasites belonging to this allelic family.
Methods
Vaccine preparation. Details of the vaccine components and
formulation have been reported elsewhere [9, 10]. In brief, the 3
vaccine candidate antigens were produced by recombinant DNA
technology within a collaborative program involving the Walter and
Eliza Hall Institute of Medical Research, Queensland Institute of
Medical Research, Biotech Australia, CSL, F. Hoffmann–La Roche,
and Roche Products Australia. All 3 antigens were expressed in
Escherichia coli with histidine tags to facilitate purification by
nickel chelate chromotography. Two of the antigens, 190LCS.T3
(Ro 45-2067) and Ag1624 (Ro 46-2924), corresponded to parts of
MSP1 and MSP2, respectively. The MSP1 antigen was the 190L
fragment from the K1 parasite line, comprising the relatively con-
served blocks 3 and 4 of MSP1 fused with a universal T cell epitope
derived from the circumsporozoite protein of P. falciparum [12].
The MSP2 antigen corresponded to the near full-length MSP2 se-
quence of the 3D7 cloned line [13, 14]. Ag1505H (Ro 45-2164)
consisted of the C-terminal 70% of RESA of the FCQ-27/PNG
parasite line [15].
The adjuvant Montanide ISA720 is an oil composition contain-
ing a natural metabolizable oil and a highly refined emulsifier from
the mannide mono-oleate family; the adjuvant was donated in bulk
by SEPPIC [9]. All 3 antigens were supplied in separate vials at a
concentration of 160 mg/mL saline–Montanide ISA720 emulsion.
Prior to use, the 3 formulations were mixed and diluted with addi-
tional emulsion to give a dose of 15 mg of each antigen in a total
volume of 0.55 mL. The placebo doses consisted of 0.55 mL of the
adjuvant emulsion.
Study area and subjects. The study was conducted in 4 villages
of the South Wosera District, East Sepik Province, Papua New
Guinea. The Wosera is an area of intense and perennial malaria trans-
mission with entomological inoculation rates (determined from in-
door landing rates) averaging around 35, 12, and 10 infectious bites
per person per year for P. falciparum, Plasmodium vivax, and Plas-
modium malariae, respectively [16]. Prevalence of asymptomatic
parasitemia in 5–9-year-old children approximates 57% for P. fal-
ciparum, 23% for P. vivax, and 4% for P. malariae [17]. Enlarged
spleen rates exceed 50%, and malaria is responsible for 20%–40%
of all fevers [18]. All healthy children 5–9 years old on the day of
screening were eligible. Exclusion criteria included parent/child
refusal, allergic predisposition, acute illness on the day of screening,
chronic illness, and impaired liver or kidney function.
Study design, cohort, and randomization. The study was a double-
blind, block-randomized within age group, placebo-controlled trial
to assess safety (reported elsewhere) and pilot efficacy of a combi-
nation of 3 candidate antigens. Since it has been debated whether
preexisting infections should be cleared before immunization, half
the children were pretreated with sulfadoxine-pyrimethamine (SP;
Fansidar, Roche). Children were allocated individually into 4 treat-
ment groups of 30 each: No-SP plus vaccine (group 1), No-SP plus
placebo (adjuvant alone; group 2), SP plus vaccine (group 3), and
SP plus placebo (group 4). Randomization was carried out in blocks
of 12 (3 of each group).
Sample size. A sample size of 120 subjects (60 each in the vac-
cine and placebo groups) was chosen to enable us to detect a 30%
reduction of parasite density (primary outcome) with 90% power
(a ¼ :05). The magnitude of reduction was chosen because it was
slightly higher than that obtained in the Tanzanian SPf66 malaria
vaccine trial, in which a 20% reduction of P. falciparum density
corresponded to a 31% reduction in clinical episodes of P. falci-
parum malaria [19].
Enrollment and immunizations. Since the adjuvant and the vac-
cine formulation had never been administered to children, the en-
rollment and immunizations were carried out in subcohorts of 12
or 24 subjects, starting with the older age group (7.5–9 years), with
10 days of observation in between.
In the week prior to vaccination, children were screened and ex-
amined, and a sample of venous blood was obtained. According to
their randomization number, the children were given either SP or a
placebo (an indistinguishable sugar tablet). During week 0, they
were injected intramuscularly in the left lateral thigh with the vac-
cine or placebo (adjuvant alone). Four weeks after the first injec-
tion, the children received a second intramuscular injection in the
right lateral thigh.
Parasitologic follow-up (weeks 8–18). Finger-prick blood
samples were obtained every 2 weeks from weeks 8 to 18 for deter-
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mination of P. falciparum parasite densities and msp2 genotypes.
Giemsa-stained blood films were examined, and the numbers of
parasites per 200 white blood cells (WBC) were recorded. The num-
ber of parasites per microliter was calculated from the WBC count.
One hundred thick-film fields were examined before a slide was de-
clared negative. All slides were examined independently by 3 mi-
croscopists to determine whether they were negative or positive
for parasites and to determine species and density. In case of dis-
agreement, a fourth microscopist (supervisor) examined the slide,
and all 4 microscopists then had to agree on the final result.
For each individual (i), we computed the geometric mean P. falci-
parum parasite density in microscopy-positive blood samples ob-
tained at weeks 8, 10, 12, 14, 16, and 18 and denoted each as gi. gi
was considered to be missing if all samples from weeks 8, 10, 12,
14, 16, and 18 were negative. gi was defined a priori in the analytical
plan as the primary outcome measure because it represents an inde-
pendent measurement for each child that is less variable than the in-
dividual parasite density assessments. Thus the primary estimate of
efficacy was calculated as follows: 1  ðV=PÞ, where V is the geo-
metric mean of the values of gi in the vaccine group, and P is the
geometric mean of the values of gi in the placebo group. Statistical
significance of the effects of vaccine and of SP pretreatment were
tested by analysis of variance of the log-transformed values of gi.
PCR–restriction fragment–length polymorphism (RFLP) analysis
genotyping. For easy storage, transport, and DNA purification,
10mL of blood pellet from the finger-prick or venous blood samples
was spotted on filter papers (Isocode Stix; Schleicher & Schuell).
After the filter papers were washed according to the supplier’s in-
structions, a triangle of filter paper was submerged in msp2 primary
PCR mix. Primary and nested PCR were performed as described
elsewhere [20]. All amplification products were digested with the
restriction enzyme Hinf I. Samples containing 3D7-type alleles sub-
sequently were digested with Dde I and ScrF I. RFLP analysis was
done as described elsewhere [20]. All samples were genotyped inde-
pendently without knowledge of the child’s identity. The genotyp-
ing of most samples was confirmed by repeating the procedure, starting
from the filter paper.
The prevalence of infection detected by PCR after vaccination
was estimated from the samples obtained at weeks 8, 10, 12, 14,
16, and 18. Prevalence in vaccine recipients was compared with
that in placebo recipients, using a logistic regression model with a
random-effect term to allow for correlations between observations
in the same child and with allowance for the effects of SP pretreat-
ment. Separate analyses were carried out for overall PCR positivity
and for each of the 2 allelic families of msp2.
Clinical surveillance (week 8–76). Morbidity monitoring con-
sisted of once-a-week visits by village reporters to all children at
their home, from week 8 to week 76, together with health facility-
based surveillance during the same period [21]. In case of symp-
toms during the previous 3 days or axillary temperature of.37.5C,
a blood sample was obtained again for determination of parasite
densities and genotypes. A clinical episode of malaria was defined
as a fever (axillary temperature .37.5C) or a history of fever in
the previous 3 days and a P. falciparum parasitemia of>8000 para-
sites/mL. This threshold has been shown elsewhere to have ade-
quate specificity and sensitivity in children in Wosera [22]. Further
analyses considered episodes with any P. falciparum parasitemia.
Kaplan-Meier survival curves were used to compare attack rates
of first or only episodes between the vaccine and placebo groups.
Statistical significance of effects of vaccine and of SP treatment
was assessed using log-rank tests. Survival analyses were also used
to compare attack rates of first or only morbid episodes between the
vaccine and placebo; this was done separately for the 2 allelic fam-
ilies of msp2. For each allelic family, the analysis included all epi-
sodes that satisfied the above case definitions and in which >1
msp2 genotype belonging to that family was detected.
Results
The study was conducted from February 1998 to September
1999. Three hundred eighty children who were between their
fifth and tenth birthdays on the planned day of screening were
identified from a demographic surveillance system. Fifty-two
percent of the parents or guardians agreed to their children’s in-
volvement. One hundred twenty-three children were screened,
3 of whom were excluded on medical grounds. All 120 children
received 2 injections within the scheduled interval and com-
pleted the parasitologic follow-up and clinical surveillance.
Baseline characteristics of treatment groups 1–4 (No-SP pre-
treatment plus vaccine, No-SP plus placebo [adjuvant alone],
SP plus vaccine, and SP plus placebo, respectively) are shown
in table 1. Sizable differences among the groups in some parasi-
tologic measures arose by chance, since there was only one
baseline measurement for each child and only a small number
of infected individuals in each group. All but 1 of the total of
1080 planned blood samples (weeks 0, 4, 6, 8, 10, 12, 14, 16,
and 18) were obtained, corresponding to a compliance rate of
99.9%, and 7532 visits were included in the morbidity surveil-
lance, representing 91% of the total possible.
Efficacy on parasite density (primary outcome). The effect
of the vaccine on parasite densities differed depending on
whether the child was pretreated with SP. Table 2 shows the
number of children with parasites during follow-up blood sam-
pling (weeks 8, 10, 12, 14, 16 and 18) and the geometric mean
parasite density in the 4 treatment groups. P. falciparum density
was significantly reduced in the vaccinated children who did
not receive SP before vaccination, compared with the density
in untreated children receiving placebo (t statistic ¼ 2:4; 29 df;
P ¼ :024). The vaccine efficacy estimate was 62% (95% confi-
dence limits [95% CLs]: 13, 84). This effect was modified signifi-
cantly by SP treatment (test of interaction F statistic ¼ 4:8; 1.43
df; P ¼ :034). Among SP-treated children, there was no signifi-
cant difference in parasite density between the vaccine and pla-
cebo groups (t statistic ¼ 1:0; 14 df; P ¼ :3). Adjustment for
baseline parasite prevalence and/or density made a negligible
difference to these results.
The difference in parasite density dynamics during follow-up
among the vaccine and placebo groups in the No-SP and the SP
groups is shown in figure 1. Substantially fewer high parasite-
mias (parasite density .500/mL) occurred in the children who
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received the vaccine formulation in the No-SP group (figure 1,
upper right ), compared with those who received placebo (3 vs.
20 slides, respectively; figure 1, upper left ). In the SP group, few
blood sample slides with high parasitemia were seen in the vac-
cine and placebo groups (9 and 7 slides, respectively; figure 1,
lower right and left ). The effect of the vaccine on parasite den-
sity could not be compared between infections with parasites of
the FC27- or 3D7-type because of the large number of mixed
infections.
Effects on prevalence, as determined by PCR. Of 360 blood
samples collected from vaccine recipients (including both SP
and No-SP groups) during follow-up, 57 (16%) were positive,
as determined by PCR, whereas 98 (27%) of the 359 placebo
samples were positive. This difference was not statistically sig-
nificant when simultaneously adjusted for the effects of repeated
assessment of the same children, SP treatment, and baseline pos-
itivity. However, when specific allelic families were considered,
the prevalence of the 3D7 dimorphic form of msp2 was found to
be significantly reduced, even allowing for repeated assessment
of the same children and for baseline presence of 3D7 parasites
(x 2
1
¼ 4:2; P ¼ :040). In the placebo group, 78 of the samples
(22%) were positive for 3D7, and, in the vaccine group, 30 of
the samples (8%) were positive for this allelic family. On the
other hand, the logistic models indicated that the vaccine made
no difference to the prevalence of FC27-type parasites. These
effects are shown in figure 2.
Among children pretreated with SP, the prevalence of both
allelic families was low in both vaccine and placebo groups for
the entire 18-week follow-up. We therefore could not assess
whether the SP pretreatment modified the effects of the vaccine
on prevalence of 3D7-type parasites.
Effects on new infection. A new infection was considered to
have occurred when an msp2 genotype that was not detected in
the same child at week 0 or 4 was found at week 8, 10, 12, 14, 16,
or 18. Twenty-one new 3D7-type infections were detected in
placebo recipients, and only 11 were detected in vaccinees. In
contrast, only 6 new FC27-type infections were found in pla-
cebo recipients, compared with 11 in vaccinees. Twenty of the
new infections were in children pretreated with SP, and 29 were
in those not pretreated. Overall, this corresponded to a vaccine
efficacy of only 19% (95% CLs: 223%, 49%) for preventing
new infections. There was a significant difference between the
allelic types in this efficacy (x 21 ¼ 4:1; P ¼ :042), but there
was no significant effect of SP pretreatment.
Effects on first or only morbid episodes. The vaccine had
no significant efficacy on the incidence of first or only fever
episodes with P. falciparum, irrespective of whether a density
cutoff was used (table 3). Similarly, using the same case defi-
nitions, there were no effects on the incidence of fever episodes
with 3D7-type parasites. In contrast, when all first or only epi-
sodes with FC27-type parasites were considered, the incidence
was found to be higher in vaccinees (log rank x 2
1
¼ 6:5;
P ¼ :01; figure 3). This effect was accounted for by the
children who were not treated with SP (for whom log rank
Table 2. Number of children with Plasmodium falciparum parasites
during parasitologic follow-up (weeks 8–18) in a phase 1–2b trial of a










Placebo 18 382.6 201, 728
Vaccine 13 144.6 89, 236
SP
Placebo 6 257.2 47, 1421
Vaccine 10 689.5 163, 2911
NOTE. gi, Individual parasite densities in blood samples obtained at weeks
8, 10, 12, 14, 16, and 18; No-SP, treatment group receiving vaccine or placebo
without SP; SP, treatment group receiving vaccine or placebo and SP.
a Determined by microscopy.
Table 1. Baseline characteristics for children in a phase 1–2b trial of a recombinant blood-stage malaria vaccine




Placebo Vaccine Placebo Vaccine
No. of enrollees 30 30 30 30
Age, mean years (SE) 7.5 (0.3) 7.4 (0.3) 7.6 (0.3) 7.6 (0.3)
Level of hemoglobin, g/L (SE) 100 (2) 101 (2) 103 (2) 101 (2)
Prevalence of parasites, %a 37 24 17 28
Geometric mean parasite density (95% CLs) 825 (389, 1751) 754 (106, 5380) 244 (53, 1123) 2326 (441, 12,252)
Overall prevalence, %b 63 37 47 43
Prevalence of 3D7-type parasites, % 50 23 33 30
Prevalence of FC27-type parasites, % 33 27 30 30
NOTE. 95% CLs, 95% confidence limits; No-SP, treatment groups receiving vaccine or placebo without SP; SP, treatment
groups receiving vaccine or placebo and SP.
a Determined by microscopy.
b Determined by polymerase chain reaction.
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x 2
1
¼ 7:0; P ¼ :008). There was no significant effect in the SP
group (x 21 ¼ 1:1; P ¼ :3). The tendency was the same for the
FC27-type episodes with densities of >8000 parasites/mL, but
the significance level was less clear-cut because of the lower
number of occurrences (x 21 ¼ 3:6; P ¼ :06). Adjustment (using
Cox regression) for the presence or allelic family of parasites
at baseline made little difference to the estimated vaccination
effects. Nor were these effects dependent on whether the
cases were detected in the health center or in the community
surveillance.
Discussion
This field trial with an asexual blood-stage malaria vaccine
provided strong evidence that Combination B vaccine is effica-
cious in reducing parasite densities (the primary outcome) in
children who are not pretreated with SP. This is the largest
reduction (62%) in parasite density that has yet been achieved
in a malaria vaccine trial in malaria-endemic areas. It is a rather
conservative estimate of the reduction in parasite load, since it
is based only on the reduction in density in parasite-positive
Figure 1. Parasite densities in 4 treatment groups in a phase 1–2b trial of a recombinant blood-stage malaria vaccine administered with or
without sulfadoxine-pyrimethamine (SP) pretreatment. No-SP + placebo, group treated with placebo only; No-SP + vaccine, group treated
with vaccine only; SP + placebo, group treated with SP and placebo; SP + vaccine, group treated with SP and vaccine. Vertical axes are on a
square-root scale.
Figure 2. Prevalence, by time point, of 3D7- and FC27-type parasites in 4 treatment groups in a phase 1–2b trial of a recombinant blood-stage
malaria vaccine administered with or without sulfadoxine-pyrimethamine (SP) pretreatment. No-SP + placebo, group treated with placebo only;
No-SP + vaccine, group treated with vaccine only; SP + placebo, group treated with SP and placebo; SP + vaccine, group treated with SP and
vaccine. Vertical axes are on a square-root scale.
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blood films. It does not take into account the reduced number of
positive blood films in the No-SP plus vaccine group, compared
with the No-SP plus placebo groups (35 vs. 48, respectively).
Nor does it consider the reduced number of children with de-
tectable parasites in the SP plus vaccine group at any time dur-
ing follow-up (13 vs. 18, respectively).
The randomization of half the children to be pretreated with
SP, a long-acting drug combination with a long elimination
period, had a substantial effect on the trial. This treatment re-
duced the number of patent infections during the first period
of the study and, therefore, reduced the power to compare vac-
cine and placebo within the treatment arm.
Although highly effective in reducing parasite density, Com-
bination B had no significant effect on the overall number of
clinical malaria episodes. There was even a tendency for vacci-
nated children to have a higher incidence of disease in the year
following immunization. This observation raises some concerns
and deserves some comments. The sample size was small. Since
the present trial was designed to provide an indication of a vac-
cine effect on parasite density and to acquire information on
safety as a prelude to a large morbidity trial in younger children,
we did not have the power to assess morbidity with confidence.
A trial of vitamin A supplementation in children 6 months to 4
years old in the present trial site [23] found very similar reduc-
tions in malaria morbidity rates and parasite densities, and this
provided the rationale for using parasite density as primary out-
come. However, although high parasite densities are generally
associated with malaria morbidity in areas where malaria is en-
demic, the association is by no means invariant [22, 24, 25]. In
another malaria vaccine trial, the effects of the vaccine on para-
site densities were strongly age dependent, but those on morbid-
ity were not [19].
The present study demonstrates a specific activity of Combi-
nation B vaccine against parasite growth and multiplication, the
putative mechanism for anti–asexual blood-stage vaccines. The
demonstration of a specific effect of the vaccine against the de-
velopment of 3D7-type infections also indicates that the activity
of Combination B is due, at least in part, to the MSP2 compo-
nent, which seems to protect children against infections with
homologous parasites. This does not preclude a contributing role
of the MSP1 and RESA components in the observed effects.
Vaccines containing only one allelic type of a polymorphic
antigen may induce immune responses that select for parasites
expressing alternative alleles. Such selection has been demon-
strated recently with a conjugate Streptococcus pneumoniae
vaccine [26] and is a major concern for Haemophilus influenzae
type b vaccination [27]. A similar selection of alternate proteins
after vaccination has been shown experimentally in the Plasmo-
dium knowlesi system [28]. The relationship between the 2 alle-
lic families of MSP2 is not one of simple competition, since
Figure 3. Kaplan-Meier survival curves comparing positive episodes of 3D7- and FC27-type parasites in subjects 8–60 weeks after treatment
with placebo or a recombinant blood-stage malaria vaccine.
Table 3. Number of children with symptomatic first or only morbid
episodes during the clinical surveillance period (weeks 8–76) of a phase
1–2b trial of a recombinant blood-stage malaria vaccine administered




Placebo Vaccine Placebo Vaccine
Fever and >8000 parasites/mL
FC27-type parasites 8 15 7 10
3D7-type parasites 7 11 7 8
Any Plasmodium falciparum parasites 11 18 12 15
Fever and .0 parasites/mL
FC27-type parasites 11 21 7 11
3D7-type parasites 12 12 10 9
Any Plasmodium falciparum parasites 18 22 14 18
NOTE. No-SP, treatment group receiving vaccine or placebo without SP;
SP, treatment group receiving vaccine or placebo and SP.
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they tend to occur together more often than expected, at least in
asymptomatic individuals [29, 30]. Hence it was difficult to pre-
dict what might be the effect of inclusion of only one allele of
MSP2 in a subunit vaccine, particularly since the MSP2 compo-
nent also contained the conserved region of the protein.
A previous case-control study suggested that msp2 FC27-
type infections are more virulent than those of 3D7-type infec-
tions in the study area [31]. Vaccination with 3D7 appears to
have favored the FC27-type parasites, contributing to an in-
creased rate of FC27-associated morbidity in vaccinated chil-
dren. It is possible that 3D7 parasites play a role in the natural
control of densities of FC27-type infections and that, by reduc-
ing the load of 3D7 parasites, the vaccine interfered with such
cross-protection.
To our knowledge, this study is the first demonstration of
vaccine-induced selection of malaria parasites in an area where
the disease is endemic and this study highlights the necessity to
monitor closely such trials by molecular means. The results of
this study imply that, for this particular vaccine-development
program, further vaccine formulations must include both allelic
families of MSP2 and these results generally argue for the de-
velopment of vaccines comprising conserved antigens and/or
multiple components covering all important allelic types.
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